US · Healthcare · Biotechnology
EPS came in at -1.44 against a street estimate of -0.55 — a miss of 161.8%.
Analysts rate Definium Therapeutics, Inc. a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $72.33.
CONFIDENT Definium reported transformational Phase III MDD results (8.1-point effect, largest ever reported). GAD pivotal data imminent. $1.1B cash runway through 2030. No Q&A held pending Voyage results. Q2 2026 Call did not segment by geography; Definium operates globally but no regional breakdown provided. No Q&A session held. Management stated on call: 'we will not be holding a question-and-answer session at the conclusion of today's prepared remarks' due to imminent Voyage results (week of Aug 10, 2026). Call was presentation-only. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.36% |
| venBio Select Advisor LLC | 5.35% |
| Driehaus Capital Management LLC | 5.09% |
| Jupiter Topco LLC | 4.18% |
| Capital World Investors | 3.99% |
| FMR Inc | 3.54% |
| T. Rowe Price Associates, Inc. | 3.46% |
| Geode Capital Management, LLC | 2.71% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 DEFINIUM THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Definium Therapeutics, Inc. (Ticker: DFTX, Nasdaq) • Incorporation: Briti | 2026-09-14 |
| Company announcement · Q3 2026 DEFINIUM THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Definium Therapeutics, Inc. (ticker: DFTX, Nasdaq-listed) • Filing date: Septe | 2026-09-08 |
| Reg FD disclosure · Q3 2026 DEFINIUM THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Definium Therapeutics, Inc. (NASDAQ: DFTX) • Incorporated in: British Col | 2026-08-12 |
| Quarterly report · Q2 2026 DEFINIUM THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $655.3 million (June 30, 2026) vs. $257.8 million ( | 2026-08-06 |
| Results announced · Q3 2026 DEFINIUM THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and investments: $1.1 billion as of June 30, 2026 (up fro | 2026-08-06 |
| Material agreement · Q2 2026 DEFINIUM THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Public offering of 20,588,236 common shares at $34.00 per share • Underwriters exercise | 2026-06-24 |
| Quarterly report · Q1 2026 DEFINIUM THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $262.5 million cash and equivalents plus $110.9 million short-t | 2026-05-07 |
| Proxy statement · Q2 2026 DEFINIUM THERAPEUTICS, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal No. 1: Elect seven directors to the Board: Carol A. | 2026-04-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 data readout timelines accelerated; multiple trials on track for 2026 MindMed, a clinical-stage biotech company, reported Q3 2025 results with strong progress on its lead candidate MM120 (LSD-based therapy). Key highlights: The company raised $258.9 million gr | 2025-11-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Definium Therapeutics, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.